Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer

MLA

Debu Tripathy, et al. “Pharmacokinetic (PK) Analyses in CSF and Plasma from TBCRC049, an Ongoing Trial to Assess the Safety and Efficacy of the Combination of Tucatinib, Trastuzumab and Capecitabine for the Treatment of Leptomeningeal Metastasis (LM) in HER2 Positive Breast Cancer.” Journal of Clinical Oncology, vol. 39, May 2021, p. 1044. EBSCOhost, https://doi.org/10.1200/jco.2021.39.15_suppl.1044.

APA

Debu Tripathy, Rashmi Krishna Murthy, Aki Morikawa, Ariel Topletz-Erickson, Antonio C. Wolff, Ian E. Krop, Erica Stringer-Reasor, Jason B White, Kim LaMaster, Michelle E. Melisko, Jennifer L. Childress, Barbara O’Brien, Kristen O. Riley, John de Groot, Vicente Valero, Mina Lobbous, Nan Lin, & Mothaffar F. Rimawi. (2021). Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. Journal of Clinical Oncology, 39, 1044. https://doi.org/10.1200/jco.2021.39.15_suppl.1044

Chicago

Debu Tripathy, Rashmi Krishna Murthy, Aki Morikawa, Ariel Topletz-Erickson, Antonio C. Wolff, Ian E. Krop, Erica Stringer-Reasor, et al. 2021. “Pharmacokinetic (PK) Analyses in CSF and Plasma from TBCRC049, an Ongoing Trial to Assess the Safety and Efficacy of the Combination of Tucatinib, Trastuzumab and Capecitabine for the Treatment of Leptomeningeal Metastasis (LM) in HER2 Positive Breast Cancer.” Journal of Clinical Oncology 39 (May): 1044. doi:10.1200/jco.2021.39.15_suppl.1044.